1. Home
  2. RVLV vs IBRX Comparison

RVLV vs IBRX Comparison

Compare RVLV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolve Group Inc.

RVLV

Revolve Group Inc.

HOLD

Current Price

$30.82

Market Cap

2.1B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.34

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVLV
IBRX
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
RVLV
IBRX
Price
$30.82
$2.34
Analyst Decision
Buy
Strong Buy
Analyst Count
13
7
Target Price
$27.08
$9.71
AVG Volume (30 Days)
1.0M
13.5M
Earning Date
02-24-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
35.78
N/A
EPS
0.78
N/A
Revenue
$1,195,039,000.00
$82,555,000.00
Revenue This Year
$8.95
$667.18
Revenue Next Year
$6.42
$93.03
P/E Ratio
$39.74
N/A
Revenue Growth
9.24
1025.95
52 Week Low
$16.80
$1.83
52 Week High
$33.68
$4.27

Technical Indicators

Market Signals
Indicator
RVLV
IBRX
Relative Strength Index (RSI) 63.37 60.13
Support Level $29.56 $1.95
Resistance Level $31.68 $2.29
Average True Range (ATR) 1.10 0.11
MACD -0.12 0.03
Stochastic Oscillator 73.97 81.65

Price Performance

Historical Comparison
RVLV
IBRX

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: